Guerbet SA

Guerbet is a French pharmaceutical group specializing in diagnostic and interventional imaging, dedicated to supporting healthcare professionals and improving patient outcomes. The company's mission revolves around developing and marketing innovative solutions, including contrast media, injection systems, medical devices, and digital and AI solutions. Guerbet's headquarters are located in Villepinte, France.

The company offers a comprehensive portfolio of products and services for various imaging modalities, including Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Cath Lab procedures, as well as Interventional Radiology and Women's Health. Key products include contrast agents such as Dotarem®, Elucirem™, Optiray®, Xenetix®, and Lipiodol®, alongside a range of injection systems, accessories, consumables, and digital solutions designed to enhance clinical decision-making.

In recent news, Guerbet has faced financial challenges stemming from an FDA warning regarding manufacturing violations at its Raleigh, North Carolina plant, which impacted revenue and profitability in late 2025 and early 2026. The company is actively implementing a remediation plan, with full normalization of the site expected by the end of fiscal year 2026. Despite these headwinds, Guerbet reported modest growth in Q1 2026, driven by strong sales in Interventional Radiology, particularly Lipiodol, and the geographical expansion of its MRI product, Elucirem. Jérôme Estampes serves as the Chief Executive Officer. Guerbet maintains a strong market position as a key player in the global contrast media market, with leadership in MRI and a stable presence in CT, while also expanding into interventional radiology and AI-driven imaging solutions.